Francois Saint-Dizier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francois Saint-Dizier has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Carol Christensen
Monell Chemical Senses Center , 3500 Market Street
2 shared publicationsGillian Watt
Pharmaron UK Ltd.
2 shared publicationsHaoguo Chen
Pharmaron Beijing, Company Ltd.
2 shared publicationsJohn Maclean
Pharmaron UK Ltd.
2 shared publicationsJohn Pollard
Pharmaron UK Ltd.
2 shared publicationsMichael Bestwick
Pharmaron UK Ltd.
2 shared publications
Latest Publications
- 3 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18856-18868
Discovery of a Novel P2X2/3 Allosteric Antagonist as an Efficient Bitter Taste Blocker
Masking the taste of unpalatable medicines is a key approach to improving treatment compliance, especially with children, where this issue is exacerbated. The P2X2/3 purinergic receptor is a ligand-gated ion channel activated by ATP that relays information from taste cells to the brain. Inhibition of this receptor has been demonstrated to block taste perception in humans and mice, suggesting that the application of a potent and short-lived antagonist directly on the tongue could provide a solution to improve treatment compliance. The previously reported dual P2X3 and P2X2/3 antagonist AF-353 (1) was used as a starting point for our campaign. A novel pyrazolopyrimidine core was identified using a scaffold-hopping strategy, which delivered compound 30 after SAR optimization. This novel antagonist displayed very high activity against P2X2/3, combined with desired physicochemical properties, resulting in a more efficacious taste-blocking effect in mice when compared to AF-353 (1).
- 3 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 18856-18868
Discovery of a Novel P2X2/3 Allosteric Antagonist as an Efficient Bitter Taste Blocker
Masking the taste of unpalatable medicines is a key approach to improving treatment compliance, especially with children, where this issue is exacerbated. The P2X2/3 purinergic receptor is a ligand-gated ion channel activated by ATP that relays information from taste cells to the brain. Inhibition of this receptor has been demonstrated to block taste perception in humans and mice, suggesting that the application of a potent and short-lived antagonist directly on the tongue could provide a solution to improve treatment compliance. The previously reported dual P2X3 and P2X2/3 antagonist AF-353 (1) was used as a starting point for our campaign. A novel pyrazolopyrimidine core was identified using a scaffold-hopping strategy, which delivered compound 30 after SAR optimization. This novel antagonist displayed very high activity against P2X2/3, combined with desired physicochemical properties, resulting in a more efficacious taste-blocking effect in mice when compared to AF-353 (1).
- Open Access
- 1 June 2026
- Published by F1000 Research Ltd in VeriXiv
Discovery of a novel P2X2/3 allosteric antagonist as an efficient bitter taste blocker
- 1 June 2026
- Published by F1000 Research Ltd in VeriXiv
Open AccessDiscovery of a novel P2X2/3 allosteric antagonist as an efficient bitter taste blocker